| Title: | Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation : a global collaborative analysis |
|---|
| Authors: | ID Gagelmann, Nico (Author)
ID Hobbs, Gabriela S. (Author)
ID Campodonico, Edoardo (Author)
ID Helbig, Grzegorz (Author)
ID Novak, Polona (Author)
ID Schroeder, Thomas (Author)
ID Schneider, Artur (Author)
ID Rautenberg, Christina (Author)
ID Reinhardt, Hans Christian (Author)
ID Bosques, Linette (Author), et al. |
|---|
| Files: |  PDF - Presentation file, download (2,08 MB)
MD5: 60E2B1E83AC83A6F4251357AE019AE3D
 URL - Source URL, visit https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.27252
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  UKC LJ - Ljubljana University Medical Centre
|
|---|
| Abstract: | Splenomegaly is the clinical hallmark of myelofibrosis. Splenomegaly at the time ofallogeneic hematopoietic cell transplantation (HCT) is associated with graft failureand poor graft function. Strategies to reduce spleen size before HCT especially after ailure to Janus kinase (JAK) inhibition represent unmet clinical needs in the field.Here, we leveraged a global collaboration to investigate the safety and efficacy ofsplenic irradiation as part of the HCT platform for patients with myelofibrosis. Weincluded 59 patients, receiving irradiation within a median of 2 weeks (range, 0.9–12 weeks) before HCT. Overall, the median spleen size prior to irradiation was 23 cm(range, 14–35). Splenic irradiation resulted in a significant and rapid spleen size reduc-tion in 97% of patients (57/59), with a median decrease of 5.0 cm (95% confidenceinterval, 4.1–6.3 cm). The most frequent adverse event was thrombocytopenia, withno correlation between irradiation dose and hematological toxicities. The 3-yearoverall survival was 62% (95% CI, 48%–76%) and 1-year non-relapse mortality was26% (95% CI, 14%–38%). Independent predictors for survival were severe thrombo-cytopenia and anemia before irradiation, transplant-specific risk score, higher-intensity conditioning, and present portal vein thrombosis. When using a propensityscore matching adjusted for common confounders, splenic irradiation was associatedwith significantly reduced relapse (p = .01), showing a 3-year incidence of 12% forsplenic irradiation versus 29% for patients with immediate HCT and 38% for patientsreceiving splenectomy. In conclusion, splenic irradiation immediately before HCT is areasonable approach in patients experiencing JAK inhibition failure and is associatedwith a low incidence of relapse |
|---|
| Keywords: | aplastic anemia, children |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Year of publishing: | 2024 |
|---|
| Number of pages: | str. 844-853 |
|---|
| Numbering: | Vol. 99, iss. 5 |
|---|
| PID: | 20.500.12556/DiRROS-29693  |
|---|
| UDC: | 616.1 |
|---|
| ISSN on article: | 0361-8609 |
|---|
| DOI: | 10.1002/ajh.27252 |
|---|
| COBISS.SI-ID: | 197183491 |
|---|
| Publication date in DiRROS: | 03.06.2026 |
|---|
| Views: | 72 |
|---|
| Downloads: | 56 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
